Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
NZ$ 0.18
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Favourable price performance
Data is available to registered users only
Data is available to registered users only
About
Pacific Edge Limited, a cancer diagnostic company, researches, develops, and commercializes diagnostic and prognostic tools for the early detection and management of cancers in New Zealand, the United States, Australia, and Singapore. It operates in two segments, Commercial and Research. The company offers Cxbladder, a genomic urine tests for the detection and management of bladder...
Company Valuation
Based on key historical and expected multiples, the stock is overvalued relative to its peers.
Data is available to registered users only
Target Price
The average target price of PEB.NZ is 0.16 and suggests 11% downside potential. Usually, this means a SELL recommendation among investment firms, or a recommendation to d
Data is available to registered users only
Buy
Sell